On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Acute and subacute bronchial effects of oral cannabinoids.|
|Author(s)||Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ|
|Journal, Volume, Issue||Clinical Pharmacology and Therapeutics 1984;35(1):26-32|
|Major outcome(s)||acute bronchodilator activity of delta 9-THC; no effect of cannabidiol; daily use of delta 9-THC not associated with tolerance|
The bronchodilating activity of oral cannabinoids was evaluated in three double-blind experiments that involved the study of dose- response and interactive relationships and the potential development of tolerance. Data indicated that delta 8-tetrahydrocannabinol (delta 8-THC), cannabinol (CBN), and cannabidiol (CBD) in maximal doses of 75 mg, 1200 mg, and 1200 mg, respectively, did not induce significant dose-related physiologic effects in experienced marijuana smokers. delta 8-THC (75 mg) was, however, associated with bronchodilation, tachycardia, and peak highs less than that after delta 9- tetrahydrocannabinol (delta 9-THC). The combinations of CBN and CBD with low-dose delta 9-THC (5 mg) did not induce significant bronchodilation but did exert interactive effects on heart rate and "high." A 20-day study of daily delta 9-THC (20 mg), CBN (600 mg), and CBD (1200 mg) did not indicate tolerance or reverse tolerance to any drug. We conclude that delta 9-THC and, to a lesser extent, delta 8-THC, have acute bronchodilator activity but that CBN, CBD, and their combinations do not provide effective bronchodilation. The daily use of delta 9-THC was not associated with clinical tolerance.
|Dose(s)||20 mg THC daily; 1200 mg cannabidiol daily|
|Duration (days)||20 days|
|Participants||experienced marihuana smokers|
|Type of publication|
|Address of author(s)|